150 related articles for article (PubMed ID: 20080926)
21. Self-reports of executive dysfunction in current ecstasy/polydrug Users.
Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
Cogn Behav Neurol; 2012 Sep; 25(3):128-38. PubMed ID: 22960437
[TBL] [Abstract][Full Text] [Related]
22. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users.
Gouzoulis-Mayfrank E; Thimm B; Rezk M; Hensen G; Daumann J
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):819-27. PubMed ID: 12921915
[TBL] [Abstract][Full Text] [Related]
23. Everyday memory deficits in ecstasy-polydrug users.
Montgomery C; Fisk JE
J Psychopharmacol; 2007 Sep; 21(7):709-17. PubMed ID: 17606476
[TBL] [Abstract][Full Text] [Related]
24. 5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study.
Wright NE; Strong JA; Gilbart ER; Shollenbarger SG; Lisdahl KM
PLoS One; 2015; 10(7):e0134708. PubMed ID: 26231032
[TBL] [Abstract][Full Text] [Related]
25. [image omitted] Verbal fluency in Spanish-speaking children: analysis model according to task type, clustering, and switching strategies and performance over time.
Filippetti VA; Allegri RF
Clin Neuropsychol; 2011 Apr; 25(3):413-36. PubMed ID: 21491348
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).
Pardo-Lozano R; Farré M; Yubero-Lahoz S; O'Mathúna B; Torrens M; Mustata C; Pérez-Mañá C; Langohr K; Cuyàs E; Carbó Ml; de la Torre R
PLoS One; 2012; 7(10):e47599. PubMed ID: 23112822
[TBL] [Abstract][Full Text] [Related]
27. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
Bedi G; Van Dam NT; Redman J
J Psychopharmacol; 2010 Feb; 24(2):233-40. PubMed ID: 18832429
[TBL] [Abstract][Full Text] [Related]
28. HTTLPR functional polymorphism in schizophrenia: executive functions vs. sustained attention dissociation.
Bosia M; Anselmetti S; Pirovano A; Ermoli E; Marino E; Bramanti P; Smeraldi E; Cavallaro R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):81-5. PubMed ID: 19818823
[TBL] [Abstract][Full Text] [Related]
29. Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in CYP2D6 and COMT.
Aitchison KJ; Tsapakis EM; Huezo-Diaz P; Kerwin RW; Forsling ML; Wolff K
J Psychopharmacol; 2012 Mar; 26(3):408-18. PubMed ID: 22303032
[TBL] [Abstract][Full Text] [Related]
30. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol.
Indlekofer F; Piechatzek M; Daamen M; Glasmacher C; Lieb R; Pfister H; Tucha O; Lange KW; Wittchen HU; Schütz CG
J Psychopharmacol; 2009 Jul; 23(5):495-509. PubMed ID: 18635709
[TBL] [Abstract][Full Text] [Related]
31. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
Fisk JE; Montgomery C; Murphy PN
Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
[TBL] [Abstract][Full Text] [Related]
32. Gene-gene effects on central processing of aversive stimuli.
Smolka MN; Bühler M; Schumann G; Klein S; Hu XZ; Moayer M; Zimmer A; Wrase J; Flor H; Mann K; Braus DF; Goldman D; Heinz A
Mol Psychiatry; 2007 Mar; 12(3):307-17. PubMed ID: 17211439
[TBL] [Abstract][Full Text] [Related]
33. Catechol O-methyltransferase Val158Met polymorphism is associated with cognitive performance in nondemented adults.
de Frias CM; Annerbrink K; Westberg L; Eriksson E; Adolfsson R; Nilsson LG
J Cogn Neurosci; 2005 Jul; 17(7):1018-25. PubMed ID: 16102234
[TBL] [Abstract][Full Text] [Related]
34. COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
Burdick KE; Funke B; Goldberg JF; Bates JA; Jaeger J; Kucherlapati R; Malhotra AK
Bipolar Disord; 2007 Jun; 9(4):370-6. PubMed ID: 17547583
[TBL] [Abstract][Full Text] [Related]
35. Everyday and prospective memory deficits in ecstasy/polydrug users.
Hadjiefthyvoulou F; Fisk JE; Montgomery C; Bridges N
J Psychopharmacol; 2011 Apr; 25(4):453-64. PubMed ID: 20123936
[TBL] [Abstract][Full Text] [Related]
36. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
Soar K; Parrott A; Turner J
J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
[TBL] [Abstract][Full Text] [Related]
37. Electrophysiological indices of altered working memory processes in long-term ecstasy users.
Nulsen C; Fox A; Hammond G
Hum Psychopharmacol; 2011 Oct; 26(7):488-97. PubMed ID: 21953632
[TBL] [Abstract][Full Text] [Related]
38. The relationships of 'ecstasy' (MDMA) and cannabis use to impaired executive inhibition and access to semantic long-term memory.
Murphy PN; Erwin PG; Maciver L; Fisk JE; Larkin D; Wareing M; Montgomery C; Hilton J; Tames FJ; Bradley B; Yanulevitch K; Ralley R
Hum Psychopharmacol; 2011 Oct; 26(7):460-9. PubMed ID: 21898599
[TBL] [Abstract][Full Text] [Related]
39. Clustering and switching processes in semantic verbal fluency in the course of Alzheimer's disease subjects: results from the PAQUID longitudinal study.
Raoux N; Amieva H; Le Goff M; Auriacombe S; Carcaillon L; Letenneur L; Dartigues JF
Cortex; 2008 Oct; 44(9):1188-96. PubMed ID: 18761132
[TBL] [Abstract][Full Text] [Related]
40. Assessing the functional significance of ecstasy-related memory deficits using a virtual paradigm.
Montgomery C; Hatton NP; Fisk JE; Ogden RS; Jansari A
Hum Psychopharmacol; 2010; 25(4):318-25. PubMed ID: 20521322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
